Search

Your search keyword '"Popat, S"' showing total 186 results
Start Over Author "Popat, S" Publisher elsevier b.v.
186 results on '"Popat, S"'

4. OC-0270 Metastases-directed SRT and systemic therapy: EORTC-ESTRO OligoCare delphi consensus recommendations

Author

Kroeze, S., Pavic, M., Stellamans, K., Lievens, Y., Becherini, C., Scorsetti, M., Alongi, F., Ricardi, U., Jereczek, B., Westhoff, P., But-Hadzic, J., Widder, J., Geets, X., Bral, S., Lambrecht, M., Billiet, C., Sirak, I., Ramella, S., Battista, I.G., Benavente, S., Zapatero, A., Romero, F., Zilli, T., Khanfir, K., Hemmatazad, H., De Bari, B., Klass, D., Adnan, S., Peulen, H., Salinas Ramos, J., Strijbos, M., Popat, S., Ost, P., and Guckenberger, M.

Published
2023
Full Text
View/download PDF

5. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.

Author

Popat, S., Baas, P., Faivre-Finn, C., Girard, N., Nicholson, A.G., Nowak, A.K., Opitz, I., Scherpereel, A., and Reck, M.

Subjects
*MESOTHELIOMA, *IMMUNE checkpoint inhibitors, *TUMOR classification, *DIAGNOSIS, *SALVAGE therapy
Abstract

• This ESMO Clinical Practice Guideline provides key recommendations for managing malignant pleural mesothelioma. • The optimal diagnostic methods, pathological evaluation and staging are described. • The authors make recommendations on the role of surgery and macroscopic complete resection as part of multimodality therapy. • The authors discuss optimal first-line, maintenance and salvage systemic therapies and immune checkpoint inhibitors. • The authors discuss the role of prophylactic, radical and palliative radiotherapy and optimal supportive care. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

13. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.

Author

Popat, S., Curioni-Fontecedro, A., Dafni, U., Shah, R., O'Brien, M., Pope, A., Fisher, P., Spicer, J., Roy, A., Gilligan, D., Gautschi, O., Nadal, E., Janthur, W.D., López Castro, R., García Campelo, R., Rusakiewicz, S., Letovanec, I., Polydoropoulou, V., Roschitzki-Voser, H., and Ruepp, B.

Subjects
*MESOTHELIOMA, *PLEURA cancer, *CANCER chemotherapy, *PEMBROLIZUMAB, *CLINICAL trials
Abstract

Malignant pleural mesothelioma (MPM) is an aggressive malignancy characterised by limited treatment options and a poor prognosis. At relapse after platinum-based chemotherapy, single-agent chemotherapy is commonly used and single-arm trials of immune-checkpoint inhibitors have demonstrated encouraging activity. PROMISE-meso is an open-label 1:1 randomised phase III trial investigating the efficacy of pembrolizumab (200 mg/Q3W) versus institutional choice single-agent chemotherapy (gemcitabine or vinorelbine) in relapsed MPM patients with progression after/on previous platinum-based chemotherapy. Patients were performance status 0–1 and unselected for programmed cell death ligand 1 (PD-L1) status. At progression, patients randomly assigned to receive chemotherapy were allowed to crossover to pembrolizumab. The primary end point was progression-free survival (PFS), assessed by blinded independent central review (BICR). Secondary end points were overall survival (OS), investigator-assessed PFS, objective response rate (ORR), and safety. Efficacy by PD-L1 status was investigated in exploratory analyses. Between September 2017 and August 2018, 144 patients were randomly allocated (pembrolizumab: 73; chemotherapy: 71). At data cut-off [20 February 2019, median follow-up of 11.8 months (interquartile range: 9.9–14.5)], 118 BICR-PFS events were observed. No difference in BICR-PFS was detected [hazard ratio = 1.06, 95% confidence interval (CI): 0.73–1.53; P = 0.76], and median BICR-PFS (95% CI) for pembrolizumab was 2.5 (2.1–4.2), compared with 3.4 (2.2–4.3) months for chemotherapy. A difference in ORR for pembrolizumab was identified (22%, 95% CI: 13% to 33%), over chemotherapy (6%, 95% CI: 2% to 14%; P = 0.004). Forty-five patients (63%) assigned to chemotherapy received pembrolizumab at progression. With follow-up to 21 August 2019 [17.5 months: (14.8–19.7)], no difference in OS was detected between groups (HR = 1.12, 95% CI: 0.74–1.69; P = 0.59), even after adjusting for crossover. Pembrolizumab safety was consistent with previous observations. Exploratory efficacy analyses by PD-L1 status demonstrated no improvements in ORR/PFS/OS. This is the first randomised trial evaluating the efficacy of pembrolizumab in MPM patients progressing after/on previous platinum-based chemotherapy. In biologically unselected patients, although associated with an improved ORR, pembrolizumab improves neither PFS nor OS over single-agent chemotherapy. • First randomised, controlled trial evaluating efficacy of an anti-PD1 agent versus chemotherapy in relapsed MPM, with immunotherapy crossover allowed. • Objective response rate was significantly improved for pembrolizumab (22% versus 6%, P = 0.004). • No improvement for independently reviewed PFS for pembrolizumab over chemotherapy (HR = 1.06, 95% CI: 0.73–1.53, P = 0.76). • No overall survival improvement for pembrolizumab over chemotherapy (HR = 1.04, 95% CI: 0.66–1.67, P = 0.85). [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

30. 29P Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results.

Author

Tiseo, M., Popat, S., Kim, H.R., Ahn, M-J., Yang, J.C., Han, J-Y., Hochmair, M.J., Lee, K.H., Delmonte, A., Garcia Campelo, M.R., Kim, D-W., Griesinger, F., Felip, E., Califano, R., Spira, A.I., Gettinger, S.N., Lin, H.M., Liu, Y., Vranceanu, F., and Camidge, D.R.

Subjects
*NON-small-cell lung carcinoma, *PROTEIN-tyrosine kinases, *CRIZOTINIB, *ANAPLASTIC lymphoma kinase
Published
2022
Full Text
View/download PDF

37. 1117P Amivantamab compared with European, real-world (RW) standard of care (SoC) in adults with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), after failure of platinum-based therapy

Author

Girard, N., Popat, S., Rahhali, N., Rodrigues, B., Schioppa, C.A., Pick-Lauer, C., Adamczyk, A., Sermon, J., Diels, J., Penton, J., and Thomas, M.

Subjects
*EPIDERMAL growth factor receptors, *NON-small-cell lung carcinoma, *INSERTION mutation
Published
2022
Full Text
View/download PDF

45. Transformation to “high grade” neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma

Author

Popat, S., Wotherspoon, A., Nutting, C.M., Gonzalez, D., Nicholson, A.G., and O’Brien, M.

Subjects
*GENETIC transformation, *NEUROENDOCRINE tumors, *DRUG resistance in cancer cells, *LUNG cancer treatment, *EPIDERMAL growth factor receptors, *PROTEIN-tyrosine kinase inhibitors, *SMALL cell lung cancer, *CISPLATIN, *GENETICS
Abstract

Abstract: Several different acquired resistance mechanisms of EGFR mutant lung adenocarcinoma to EGFR-tyrosine kinase inhibitor (TKI) therapy have been described, most recently transformation to small cell lung carcinoma (SCLC). We describe the case of a 46-year-old female with relapsed EGFR exon 19 deletion lung adenocarcinoma treated with erlotinib, and on resistance, cisplatin-pemetrexed. Liver rebiopsy identified an afatinib-resistant combined SCLC and non-small cell carcinoma with neuroendocrine morphology, retaining the EGFR exon 19 deletion. This case highlights acquired EGFR-TKI resistance through transformation to the high-grade neuroendocrine carcinoma spectrum and that that such transformation may not be evident at time of progression on TKI therapy. [Copyright &y& Elsevier]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results